SFY0 Stock Overview A clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. More details
Risk Analysis + 3 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Theriva Biologics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Theriva Biologics Historical stock prices Current Share Price US$2.42 52 Week High US$14.00 52 Week Low US$2.42 Beta 1.34 1 Month Change 0% 3 Month Change -0.82% 1 Year Change -75.92% 3 Year Change -96.47% 5 Year Change -97.21% Change since IPO -99.99%
Recent News & Updates Theriva Biologics, Inc. has filed a Follow-on Equity Offering. Dec 11
Theriva Biologics, Inc. Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma Oct 16
Theriva Biologics, Inc. Announces Positive Outcome of Data and Safety Monitoring Committee (Dsmc) Review in Phase 1B/2A Clinical Trial of Syn-004 (Ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients Oct 03
Theriva Biologics, Inc., Annual General Meeting, Oct 31, 2024 Sep 20
High number of new and inexperienced directors Sep 13 Theriva Biologics, Inc. has filed a Follow-on Equity Offering. Sep 11
See more updates Theriva Biologics, Inc. has filed a Follow-on Equity Offering. Dec 11
Theriva Biologics, Inc. Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma Oct 16
Theriva Biologics, Inc. Announces Positive Outcome of Data and Safety Monitoring Committee (Dsmc) Review in Phase 1B/2A Clinical Trial of Syn-004 (Ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients Oct 03
Theriva Biologics, Inc., Annual General Meeting, Oct 31, 2024 Sep 20
High number of new and inexperienced directors Sep 13 Theriva Biologics, Inc. has filed a Follow-on Equity Offering. Sep 11
New minor risk - Shareholder dilution Aug 18
New major risk - Financial position Aug 14
Theriva Biologics, Inc. Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma Aug 02
Theriva Biologics, Inc Announces U.S. Food and Drug Administration Granted Fast Track Designation May 25 Theriva Biologics, Inc. has filed a Follow-on Equity Offering in the amount of $1.235303 million. May 03
Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma Apr 23
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma Feb 07
Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023 Oct 24
Theriva Biologics, Inc. Announces Presentation at Esmo Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating Vcn-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck Oct 18
Theriva Biologics, Inc., Annual General Meeting, Oct 02, 2023 Aug 15
New minor risk - Shareholder dilution Aug 11
New major risk - Market cap size Jul 26
Theriva Biologics Appoints Ramon Alemany as Senior VP of Discovery May 24
Theriva Biologics, Inc. Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients Feb 17
Theriva Biologics, Inc. Announces First Patient Dosed in VIRAGE, A Phase 2B Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma Jan 18
Theriva Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors Jan 10
High number of new and inexperienced directors Nov 16
Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004 Nov 04
Theriva Biologics, Inc. Announces Presentation at the 14th International Oncolytic Virotherapy (IVOC) Conference Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck Oct 25
Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (Dsmc) Review in Phase 1B/2A Clinical Trial of Syn-004 (Ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients Sep 28
Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck Sep 07
Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck Sep 06
Synthetic Biologics, Inc., Annual General Meeting, Sep 30, 2022 Aug 12 Synthetic Biologics, Inc. announced that it expects to receive $3 million in funding from MSD Partners, L.P.
Synthetic Biologics, Inc. Notifies Clearance of Safety Evaluation Period Jul 15
High number of new and inexperienced directors Jun 02
Synthetic Biologics, Inc. Reports Positive Safety Data on Syn-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial May 12
Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline May 08
Synthetic Biologics, Inc. Announces Peer-Reviewed Publication of Phase 1 Trial of Intravenous VCN-01 Oncolytic Adenovirus in Patients with Advanced Solid Tumors Mar 29
Synthetic Biologics, Inc. (NYSEAM:SYN) signed a definitive agreement to acquire VCN Biosciences SL from Grifols Innovation and New Technologies Limited and others for $85.6 million. Dec 15
Synthetic Biologics Provides Update on Syn-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical Trial Jun 30
Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards May 27
Synthetic Biologics, Inc. Announces Clinical Development and Operational Update Mar 06
Insider recently bought €144k worth of stock Mar 05
Synthetic Biologics, Inc. to Report Fiscal Year 2020 Results on Mar 04, 2021 Feb 26
New 90-day high: €1.23 Jan 05
Synthetic Biologics, Inc. Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol Dec 23
Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American Nov 25
Synthetic Biologics, Inc. Announces Executive Changes Nov 13
Synthetic Biologics, Inc. to Report Q3, 2020 Results on Nov 10, 2020 Nov 05
New 90-day low: €0.23 Oct 30
New 90-day low: €0.24 Oct 13
Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2B Clinical Study of SYN-010 in IBS-C Patients Oct 03
New 90-day low: €0.37 Sep 26
New 90-day high - €0.59 Jul 31
Synthetic Biologics, Inc. to Report Q2, 2020 Results on Aug 06, 2020 Jul 31 Shareholder Returns SFY0 DE Biotechs DE Market 7D 0% -0.8% -1.6% 1Y -75.9% -13.0% 6.8%
See full shareholder returns
Return vs Market: SFY0 underperformed the German Market which returned 7.8% over the past year.
Price Volatility Is SFY0's price volatile compared to industry and market? SFY0 volatility SFY0 Average Weekly Movement n/a Biotechs Industry Average Movement 6.9% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: SFY0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine SFY0's volatility change over the past year.
About the Company Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.
Show more Theriva Biologics, Inc. Fundamentals Summary How do Theriva Biologics's earnings and revenue compare to its market cap? SFY0 fundamental statistics Market cap €2.70m Earnings (TTM ) -€25.21m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SFY0 income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$26.69m Earnings -US$26.69m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -11.75 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio 0.7%
How did SFY0 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/11/20 00:32 End of Day Share Price 2024/08/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Theriva Biologics, Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners Keay Nakae Ascendiant Capital Markets LLC Timothy Chiang BTIG
Show 7 more analysts 
